GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Subscribe To Our Newsletter & Stay Updated
